为NSCLC优化奥西默提尼布:准耐药性和探索组合疗法
Yan-You Liao1, Chia-Luen Tsai2, Hsiang-Po Huang2
1Department of Medicine, National Taiwan University College of Medicine, Taipei 100233, Taiwan.
Cancers
|February 13, 2025
概括
第三代EGFRTKI改善了非小细胞肺癌 (NSCLC) 的结果,但抗药性出现了. 组合疗法将奥西默蒂尼布与其他治疗方法结合起来,有望克服EGFR突变NSCLC的耐药性并改善存活率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 具有EGFR突变的非小细胞肺癌 (NSCLC) 是一个主要的全球健康问题.
- 第三代EGFR氨酸激酶抑制剂 (TKI),如奥西默蒂尼布是有效的,但获得的耐药性是不可避免的.
- 抵抗的机制包括目标突变 (例如C797S),途径激活 (例如MET放大) 和瘤微环境变化.
研究的目的:
- 审查第三代EGFRTKI在NSCLC中的组合疗法的不断变化的格局.
- 探索将奥西默蒂尼布与放射治疗,抗血管原剂,免疫检查点抑制剂和其他向药物配对的策略.
- 讨论这些组合方法的生物学理由,临床前数据和临床证据.
主要方法:
- 临床前研究和临床试验的文献综述.
- 分析涉及 osimertinib 的组合策略.
- 评估抵抗机制及其规避方法.
主要成果:
- 组合疗法旨在增强或延长第三代EGFRTKI的疗效.
- 正在制定策略,以克服各种抵抗机制,包括目标突变和途径激活.
- 组合可以改善存活率,并保持EGFR突变NSCLC中有利的安全性.
结论:
- 组合疗法是解决对第三代EGFRTKI耐药性的有希望的策略.
- 整合各种方式的个性化治疗方法对于持久的反应至关重要.
- 需要进一步的研究和临床试验来优化这些组合,以改善EGFR突变NSCLC患者的治疗结果和生活质量.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.7K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K